Enlitic Expands US Footprint with Ensight Deployment
Enlitic Inc. (ASX: ENL) has deployed its cloud-based Ensight platform with Colorado-based Radiology Imaging Associates (RIA), marking its first US implementation through the Intelerad integration. The deployment is Enlitic’s second Ensight rollout since May 2026, with additional go-lives expected during H2 FY26. The initial phase of the three-year agreement is expected to generate approximately US$50,000 in profitable annual recurring SaaS revenue.
The implementation currently covers selected Ensight modules integrated into RIA’s existing medical imaging environment, allowing adoption without replacing current systems. Its modular structure also provides flexibility to add more sites, users, workflows and capabilities over time.
Strategically, the deployment validates Enlitic’s recurring-revenue model and Intelerad integration while establishing a live US customer reference. Potential expansion across RIA’s network could support higher recurring revenue and strengthen Enlitic’s commercial presence in the US medical imaging market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Enlitic Expands US Footprint with Ensight Deployment
Enlitic Inc. (ASX: ENL) has deployed its cloud-based Ensight platform with Colorado-based Radiology Imaging Associates (RIA), marking its first US implementation through the Intelerad integration. The deployment is Enlitic’s second Ensight rollout since May 2026, with additional go-lives expected during H2 FY26. The initial phase of the three-year agreement is expected to generate approximately US$50,000 in profitable annual recurring SaaS revenue.
The implementation currently covers selected Ensight modules integrated into RIA’s existing medical imaging environment, allowing adoption without replacing current systems. Its modular structure also provides flexibility to add more sites, users, workflows and capabilities over time.
Strategically, the deployment validates Enlitic’s recurring-revenue model and Intelerad integration while establishing a live US customer reference. Potential expansion across RIA’s network could support higher recurring revenue and strengthen Enlitic’s commercial presence in the US medical imaging market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au